8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): April 25, 2007

                                  NEOSTEM, INC.
             (Exact name of registrant as specified in its charter)


            Delaware               0-10909                   22-2343568
            --------               -------                   ----------
        (State Or Other          (Commission                (IRS Employer
         Jurisdiction Of         File Number)             Identification No.)
         Incorporation)



      420 Lexington Avenue, Suite 450
            New York, New York                                 10170
- -------------------------------------------------------------------------------
 (Address of principal executive offices)                   (Zip Code)



       Registrant's telephone number, including area code: (212)-584-4814

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[_] Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-4(c))





Item 8.01.        Other Events.

         On April 26, 2007, the Company issued a press release announcing two
licenses issued to the Company by the New York State Department of Health as
described in the press release, a copy of which is attached as Exhibit 99.1.






Item 9.01.        Financial Statements and Exhibits.

(d)  Exhibits.

         Exhibit 99.1      Press Release





                                    SIGNATURE
                                    ---------

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                       NEOSTEM, INC.



                                       By: /s/ Catherine M. Vaczy
                                       -----------------------------------------
                                              Catherine M. Vaczy
                                              Vice President and General Counsel


Dated: April 27, 2007





                                  EXHIBIT INDEX


Exhibit Number    Description
- --------------    -----------
Exhibit 99.1      Press Release

EX-99.1

                                                                    Exhibit 99.1

  NeoStem Receives Licenses from New York State to Begin Operations

     Two State Licenses Allow Stem Cell Collections to Immediately
   Begin from NeoStem Clients in New York for Storage in California
                               Facility


    NEW YORK--(BUSINESS WIRE)--April 26, 2007--NeoStem, Inc.
(OTCBB:NEOI), the first company to specialize in the collection,
processing and storage of stem cells from healthy adult donors for
personal use in times of critical medical need, has announced that the
New York State Department of Health has issued two provisional
licenses to allow the Company to begin commercializing its next
generation stem cell collection services in New York.

    The first license approves NeoStem's California facility to store
stem cells collected from the peripheral blood of clients in the State
of New York as specified in the license. Specifically, it allows for
comprehensive tissue procurement services, permitting tissue
collection, processing and storage at the California facility of
hematopoietic progenitor cells.

    The second license approves limited tissue procurement services,
permitting solicitation relating to the collection of hematopoietic
progenitor cells from the peripheral blood of autologous donors at
NeoStem's New York City location.

    NeoStem will begin adult stem cell collections through its
relationship with a New York approved stem cell collection service
provider and will seek to continue to add to its network of collection
providers and hospitals.

    "We are very excited to have been able to receive authorization to
begin operations in New York and offer our next generation services to
the millions of citizens of the State," said Dr. Robin Smith, Chief
Executive Officer of NeoStem. "We believe that these licenses are a
further validation of our proprietary process and of our business
model."

    NeoStem is developing a nationwide network of adult stem cell
collection centers, enabling people to donate and store their own stem
cells for personal use years or decades later--providing an accessible
supply of healthy, genetically matched stem cells for potential
therapeutic use.

    NeoStem's first-to-market competitive advantage positions the
Company to capitalize on the hundreds of stem cell-based therapy
research programs and clinical trials currently underway. The Company
believes these programs will result in stem cell-based therapies
becoming available, and that NeoStem clients could be among the first
to benefit from the life saving progress that has already been made
for such debilitating conditions as cancer, heart disease, diabetes,
multiple sclerosis, lupus, and many others.

    About NeoStem, Inc.

    NeoStem is a biotechnology services company enhancing the delivery
of adult stem cell therapeutics to health-conscious consumers. The
Company is developing a nationwide network of adult stem cell
collection centers, enabling people to donate and store their own stem
cells with NeoStem for personal use years or decades later in times of
critical medical need.

    The proprietary NeoStem technologies empower health-conscious
consumers to help protect their future health by undergoing treatment
with their own stem-cells - providing an accessible supply of healthy,
genetically matched stem cells for use in the eventuality of illness.

    Currently underway are hundreds of stem cell-based research
programs and clinical trials investigating the use of these
non-controversial adult stem cells, such as those collected from
donors under NeoStem's methods. As the nation's population ages and
encounters serious age-related and congenital health issues, NeoStem
has positioned itself as a leader in the fast-growing national trend
toward personal "bio-insurance."

    The Company's non-capital intensive business plan is a service
model that is completely scalable and can be quickly implemented, thus
minimizing risk levels ordinarily related to most long-term
biopharmaceutical research and development. Under its strategic
business plan, NeoStem has begun opening a nationwide network of adult
stem cell collection facilities. Its stem cell collection systems will
be located in existing physician offices and medical facilities, where
the procedures and care can be administered by trusted personal
doctors and medical professionals.

    For more information, please visit: www.neostem.com. For other
information and resources about the Company, visit
http://www.trilogy-capital.com/tcp/neostem/. To view current stock
quotes and news, visit
http://www.trilogy-capital.com/tcp/neostem/quote.html. To view a fact
sheet about the company, visit
http://www.trilogy-capital.com/tcp/neostem/factsheet.html.

    Forward-Looking Statements

    Certain statements in this press release constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
concerning the ability of NeoStem, Inc. ("the Company") to develop the
adult stem cell business, the future of regenerative medicine and the
role of adult stem cells in that future, the future use of adult stem
cells as a treatment option and the potential revenue growth of the
Company's business. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors, which may cause the
actual results, performance or achievements of the Company, or
industry results, to be materially different from any future results,
performance, or achievements expressed or implied by such
forward-looking statements. The Company's ability to enter the adult
stem cell arena and future operating results are dependent upon many
factors, including but not limited to (i) the Company's ability to
obtain sufficient capital or a strategic business arrangement to fund
its expansion plans; (ii) the Company's ability to build the
management and human resources and infrastructure necessary to support
the growth of its business; (iii) competitive factors and developments
beyond the Company's control; (iv) scientific and medical developments
beyond the Company's control; (v) the Company's inability to obtain
appropriate state licenses or any other adverse effect or limitations
caused by government regulation of the business; and (vi) other risk
factors discussed in the Company's periodic filings with the
Securities and Exchange Commission which are available for review at
www.sec.gov under "Search for Company Filings."

    Pursuant to an October 1, 2006 agreement, Consulting For Strategic
Growth I, Ltd. ("CFSG1") provides the Company with consulting,
business advisory, investor relations, public relations and corporate
development services, for which CFSG1 receives a fixed monthly fee for
the duration of the agreement and received shares of NeoStem's common
stock. Independent of CFSG1's receipt of cash or other compensation
from the Company, CFSG1 may choose to purchase the common stock of the
Company and thereafter sell those shares at any time it deems
appropriate to do so. For more information, please visit
www.cfsg1.com.

    CONTACT: NeoStem, Inc.
             Robin Smith, Chief Executive Officer, 212-584-4180
             rsmith@neostem.com
             www.neostem.com
             or
             Consulting for Strategic Growth 1
             Stanley Wunderlich/Daniel Stepanek, 800-625-2236
             Fax: 212-337-8089
             http://www.cfsg1.com
             or
             Financial Communications
             Trilogy Capital Partners
             Ryon Harms, 800-592-6067
             ryon@trilogy-capital.com